Arrowhead Aims for HBV IND in Early 2013, Releases Preclinical Data from Program | GenomeWeb

Just months after adding a hepatitis B treatment to its pipeline, Arrowhead Research's top official this week said that the company expects the program to yield an investigational new drug application in the first half of next year.

Arrowhead, which just released its fiscal second-quarter financial results, also announced preclinical data showing that siRNAs formulated in the company's proprietary dynamic polyconjugate, or DPC, technology could significantly reduce levels of the viral RNA and DNA in animal models of the disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.